Al-Sawaf O et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: Extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol 2021;39(36):4049-60. Abstract
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. EHA 2022;Abstract S148.
Barr PM et al. Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 2022;6(11):3440-50. Abstract
Davids MS et al. ReVenG: A phase 2 study of venetoclax plus obinutuzumab retreatment in patients with relapsed chronic lymphocytic leukemia. ASH 2021;Abstract 2634.
Ghia P et al. First-line treatment with ibrutinib (ibr) plus venetoclax (ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 Captivate study. ASH 2021;Abstract 68.
Gordon MJ et al. The chronic lymphocytic leukemia comorbidity index (CLL-CI): A three-factor comorbidity model. Clin Cancer Res 2021;27(17):4814-24. Abstract
Hillmen P et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial. ASH 2021;Abstract 642.
Jain N et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: A nonrandomized phase 2 trial. JAMA Oncol 2021;7(8):1213-9. Abstract
Mato AR et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. EHA 2022;Abstract S147.
Mato AR et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet 2021;397(10277):892-901. Abstract
Mato AR et al. Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: Results from the informCLL registry. Clin Lymphoma Myeloma Leuk 2020;20(3):174-83.e3. Abstract
Mato AR et al. Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: A prospective cohort study of 1494 patients across 199 US centres. Br J Haematol 2016;175(5):892-903. Abstract
Munir T et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (ibr+ven) versus chlorambucil plus obinutuzumab (clb+o) for first-line treatment of CLL in elderly or unfit patients: The Glow study. ASH 2021;Abstract 70.
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. ASCO 2021;Abstract 7509.
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. ASCO 2022;Abstract 7539.
Siddiqi T et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2022;139(12):1794-806. Abstract
Stephens DM et al. Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902). ASCO 2021;Abstract TPS7567.
Tam C et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Van der Straten L et al. Conditional relative survival among patients with chronic lymphocytic leukaemia: A population-based study in the Netherlands. EJHaem 2022;3(1):180-3. Abstract
Wierda WG et al. Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. ASCO 2022;Abstract 7519.